Supriya Lifescience: Choice Institutional Equities Recommends 'Buy' with Rs 1030 Target

• Choice Institutional Equities maintains 'Buy' rating for Supriya Lifescience with an unchanged target price of Rs 1030.
• The company is expected to achieve strong growth driven by new product launches and expansion in regulated markets.
• Revenue is projected to grow at a Compound Annual Growth Rate (CAGR) of approximately 20% from FY25 to FY28E.
• A planned margin contraction is anticipated in FY26, but expansion is expected from FY28 due to leadership in niche therapies and strong backward integration.